Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report issued on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Price Performance

Shares of Agile Therapeutics stock opened at $1.51 on Thursday. The stock has a 50-day simple moving average of $1.48 and a 200-day simple moving average of $0.88. Agile Therapeutics has a 52-week low of $0.20 and a 52-week high of $2.63. The firm has a market cap of $10.35 million, a price-to-earnings ratio of -0.41 and a beta of 1.58.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter. The business had revenue of $5.58 million for the quarter.

Hedge Funds Weigh In On Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 10.92% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.